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ABSTRACT 
 
Purpose of review: An analysis of the technological implementation of 
extracorporeal CO2 removal (ECCO2R ) techniques, and of its clinical 
application. A new classification of ECCO2R based on technological 
aspects, clinical properties and physiological performances, is proposed. 
 
Recent findings: The use of a ventilation with lower tidal volumes have 
been proved successful in Acute Respiratory Distress Syndrome (ARDS) 
patients but can be extremely problematic, especially when dealing with 
respiratory acidosis. The implementation of extracorporeal CO2 removal 
devices can represent the missing link between prevention of ventilator 
induced lung injury and pH control.  ECCO2-R has attracted increasing 
interest because new less invasive approaches allowing an easier 
management of ARDS patients. Recent studies have also shown that 
ECCO2-R can also be used in patients with exacerbation of Chronic 
Obstructive Pulmonary Disease (COPD) and as bridge to lung 
transplantation. 
 
Summary: The future ventilatory management of patients with acute 
respiratory failure may include a minimally invasive extracorporeal 
carbon dioxide removal circuit associated with the least amount of 
ventilatory support (non-invasive in COPD and/or invasive in ARDS) to 
minimize sedation, prevent ventilator-induced acute lung injury, and 
nosocomial infections.  Randomized clinical trials in the pipeline will 
confirm this fascinating hypothesis.   
 
 
 
Key words: Extra-Corporeal CO2Removal (ECCO2R); ECMO; protective 
ventilation; lung support; ventilator induced lung injury (VILI). 
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Mechanical ventilation (MV) is the main form of life support for 
patients with acute respiratory failure, and can resolve the impairment of 
gas exchange alteration in the vast majority patients with acute 
respiratory failure.[1] However, evidences have progressively emerged 
suggesting that MV, although indispensable for survival, may worsen the 
injured lung and may increase mortality rate if inappropriately 
administered.[2, 3] This is particularly true for acute respiratory distress 
syndrome (ARDS), where several studies demonstrated that the main 
reason for high mortality (30-50%) is not the severe hypoxemia but rather 
multi-organ failure (kidneys, heart, liver, etc.), potentially caused by the 
translocation of various mediators from the lungs through the systemic 
circulation to peripheral organs caused and/or augmented by artificial 
ventilation (ventilator-induced lung injury, VILI). 
 
The randomized trial carried out by the National Institute of Health 
demonstrated that ventilating patients with a tidal volume (VT) of 6 ml/kg 
(calculated from predicted body weight, PBW), and with a maximum 
end-inspiratory plateau pressure (PPLAT) of 30 cmH2O instead of 
ventilating patients with a VT of 12 ml/kg PBW decreased mortality from 
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39.8% to 31%. [4] However, observational studies carried out in Europe 
and in the US demonstrated that there was poor compliance by clinicians 
in reducing ventilation volumes and pressures in order to minimize 
iatrogenic damage caused by mechanical ventilation.  A major reason for 
the underuse of protective ventilatory strategies is the hypercapnia caused 
by the reduction in ventilatory volumes.  Furthermore, recent studies have 
shown that lung hyperinflation still occurs in approximately 30% of 
ARDS patients even though they are being ventilated “correctly” using 
the ARDSNet strategy [5]. These studies also suggested that some 
patients may benefit from a further reduction of VT even when PPLAT is 
less than 30 cmH2O. [5, 6] Bellani and coworkers recently assessed the 
intensity of pulmonary inflammation during mechanical ventilation using 
positron-emission tomography (PET) imaging of (18F) fluoro-2-deoxy-
D-glucose to detect the presence of metabolically active inflammatory 
cells. [7] They showed that PPLAT is significantly correlated with 
metabolic activity, and the correlation increases steeply above 26-27 
cmH2O thus suggesting that further limitation of ventilation to values of 
PPLAT of 25 cmH2O or lower may be associated with lower degree of 
pulmonary inflammation due to less VILI. [7] (**). 
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The idea of partial support (removing only carbon dioxide, with 
little to no impact on oxygenation: partial extracorporeal support) was 
proposed in 1977 by Kolobow [8, 9] and Gattinoni.[10] These authors 
suggested that applying only a few ventilator breaths at low volumes and 
low peak inspiratory pressures (“lung rest”) could prevent damage to the 
compromised lungs. To reduce complexity, expenses, and side effects of 
extracorporeal lung assistance, Pesenti and coworkers modified an 
extracorporeal circuit designed for renal replacement therapy by adding 
to the circuit an oxygenator and proposed the concept of removing “only 
a portion of carbon dioxide production” to allow less traumatic ventilator 
settings.[11] This hypothesis was developed taking into consideration the 
original observation of Sherlock and coworkers who found that patients 
treated with haemodialysis experienced a transient hypocapnia, 
hypoventilation and hypoxemia due to the capacity of the hemofilter to 
remove a significant amount of CO2.[12] What Kolobow, Gattinoni and 
Pesenti therefore proposed may be interpreted nowadays as the optimal 
protective ventilatory strategy that, “disconnecting” oxygenation 
(provided using the “residual” functional lungs using PEEP and high 
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FiO2) from CO2 clearance (performed used extracorporeal circuit and 
membrane lungs), may minimize/prevent VILI.  
 
CARBON DIOXIDE REMOVAL: PHISIOLOGY AND 
TECHNIQUES 
 
The use of extracorporeal circuits to support respiratory functions 
may be described using a “continuous model” that analyze and integrates 
the technological aspects (type of pump, characteristics of the 
oxygenator, type and size of catheter), the clinical properties (kind of 
surgical approach) and the physiological performances (amount of 
oxygen transferred to the patient and of carbon dioxide removed from the 
patient).[13] (Table 1). 
 
The lowest complexity level is represented by renal support that 
requires very low blood flows, is less invasive for the patients requiring 
low primer volumes and a small coaxial catheter. With this technique 
carbon dioxide is extracted although a very low levels.[12, 14] 
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At the other extreme of the complexity scale, total extracorporeal 
support (ECMO) is able to completely supply the physiological blood 
gas exchanges, normally performed by the native lungs and is therefore 
capable of delivering oxygen and of removing CO2 equal to the entire 
metabolic needs of the patient.  It is an invasive and complex system, 
which needs high blood flows (equivalent to the entire cardiac output) 
and high diameter cannulation. It is also necessary to use high heparin 
dosage and elevated volume of priming.  This device can be connected to 
patient with a venous-arterial (V-A) setting, therefore in parallel with the 
pulmonary circulation, also able to support the cardiac function, or in a 
venous-venous (V-V) setting, sequentially to the pulmonary circulation, 
preferred in case on respiratory failure alone. 
Partial extracorporeal support (ECCO2-R) represents the 
intermediate level of technical complexity. V-V ECCO2R needs a 14Fr 
coaxial catheter, to allow a blood flow of 0.3-0.5 l/min that is constantly 
guarantee by a roller non-occlusive pump designed to minimize 
hemolysis; blood is driven through an oxygenator membrane, which is 
connected to an oxygen source of 6-8 l/min.  Some devices also include 
an hemofilter is series with the oxygenator to allow the extraction of 
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plasmatic water that is then reinfused in the circuit in order to lower 
hematocrit and prevent blood clotting.[15, 16] (**) 
A centrifugal pump, that creates a radial flow going through an 
annular fiber oxygenator, has also been used in other veno-venous 
ECCO2R systems. This design maximizes the exchange surface, and 
therefore the device efficiency.[15] Both technological implementations 
are able to remove up to 25% of carbon dioxide production, and can 
transfer no more than 10 ml/min of oxygen.  Low dose of heparin (4-18 
IU/min) are necessary to avoid clotting occurrence.[15-17] 
 
CLINICAL USE OF ECCO2R  
A brief overview of past years studies exploring ECCO2R 
techniques safety and feasibility is shown in Table 2. 
 
ARDS 
Gattinoni and coworkers reported the first systematically collected 
clinical experience of the use of ECCO2R in patients with severe ARDS.  
MV was limited to apneic oxygenation and to 3-5 sighs every minute 
with a peak inspiratory pressure < 35-45 cmH2O; PEEP ranged between 
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15 and 25 cmH2O.  Carbon dioxide removal was performed using a 
pump-driven veno-venous bypass allowing blood flow to pass through 
two membrane lungs (9 m2 total membrane surface area).  Extracorporeal 
blood flow was progressively increased from 200 to 300 mL/min to the 
selected maintenance flow (20-30 % of cardiac output).  Although the 
observed mortality rate was lower than expected, there was no concurrent 
randomized control group; as well, several episodes of severe bleeding 
were reported.[18] In 1993 Brunet and coworkers achieved a mortality 
rate of 50% in ARDS patients, utilizing a V-V ECCO2R coupled with 
protective ventilation that reached a maximum tidal volume of 325ml. 
They also reported a 21% of hemorrhagic events and an 8% of peripheral 
vascular problems.[19] One year later, Morris and coworkers presented 
results of a randomized controlled trial in ARDS patients that 
investigated the use of Pressure Controlled Inverse-Ratio Ventilation vs 
ECCO2R techniques associated to MV. The trial, showing no significant 
difference in survival (38%) between the two groups, also highlighted 
numerous episodes of severe bleeding and the need of major 
anticoagulation with consequent hemorrhagic complications.[20]   
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In 2006 Bein and coworkers published a retrospectively experience 
with an artero-venous pumpless device with an interposed membrane 
oxygenator sustained by patients hemodynamic.  This artificial lung was 
able to remove up to 50% of the total body CO2 production, with a blood 
flow of around 1-2 l/min.  Authors reported occurrence of serious 
complications in 24,4% of patients with also episodes of ischemia of 
lower limbs after arterial cannulation.[21] 
Under these circumstances, the clinical and technological 
implementation of ECCO2-R implemented until few years ago is closer to 
full extracorporeal support, than to what envisioned in the “simple” 
devices as described in Table 1. The more invasive and/or complex 
systems are characterized by: a) flow equal or higher than 1000 ml; b) 
wide bore catheters; c) high doses of heparin; d) large volumes of blood 
to “prime” the circuit; e) numerous blood transfusion due to loss in the 
circuitry and from the accesses. The rates of major complications 
reported in clinical studies using ECCO2-R are reported in TABLE 2B.  
These data help explain why ECCO2-R has been limited to the sickest 
patients in whom all other treatments have failed [22] and to centers with 
large expertise.[23, 24] 
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In 2009 Terragni and coworkers presented a ventilation model of 
very low VT (4ml/kg of predicted body weight) for severe ARDS patients 
that, despite a ventilation setting derived from the ARDSnet Trial [4], 
showed morphological evidence of tidal hyperinflation.[5] This 
ventilatory model, that was proven to be able to decrease inflammatory 
markers associated with VILI, was coupled with a V-V ECCO2R device, 
which allowed to a safely and efficiently manage of acidosis resulted 
from Vt reduction. [16]  
The device used in Terragni’s study represents a modification of 
renal replacement therapy circuits, and is characterized by: a) veno-
venous by-pass systems; b) extracorporeal blood flow of 0.3-0.5 
litres/min; c) smaller bore catheters or a single co-axial catheter similar 
to those currently used for renal ultrafiltration procedures; d) very low 
doses or no heparin; e) minimal volumes for “priming”.  This 
technological implementation of LFPPV–ECCO2-R is therefore closer to 
device for renal replacement therapy than full ECMO (TABLE 1) and 
may explain the lack of significant side effects during the use of low-flow 
CO2 removal by-pass (TABLE 2B). 
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Chronic Obstructive Pulmonary Disease (COPD) 
ECCO2R techniques could also represent a revolutionary tool for the 
approach of other clinical situations like chronic obstructive pulmonary 
disease (COPD) exacerbations treatment in patients at risk of non-
invasive ventilation failure, or the intracranial bleeding management 
when associated to severe ARDS.  Garcia and coworkers recently 
presented preliminary data on the attempt to optimize ECMO in patients 
with COPD to reduce ventilatory support.  The study reports 10 patients 
(mean age of 45±14 years,) treated with ECMO during weaning from all 
respiratory support or as bridge to lung transplant. The mean duration of 
extracorporeal membrane oxygenation was 20 (9–59) days, with average 
mean blood flows of 3.5 (1.6–4.9) L/min, and levels of CO2 removal and 
O2 transfer of 228 (54–570) mL/min and 127 (36–529) mL/min, 
respectively. Six of 10 patients were weaned from respiratory support or 
underwent transplantation and survived to discharge from the hospital. 
The remaining 4 patients died of sepsis and withdrawal of care.[25] (**) 
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Bridge to lung transplant 
ECCO2R devices with pump support, have been developed as bridges to 
lung transplant in patients with severe, unresponsive respiratory failure. 
In a recent report ECCO2 R low flow devices have been proved simple 
and efficient methods to support patients with mild hypoxia and severe 
hypercapnia refractory to MV.[26](**) Ruberto et all reported also the 
experience  of veno-venous extracorporeal support in primary graft 
dysfunction after single lung transplant with a control of respiratory 
acidosis, decrease of PaCO2 and reduction of ventilatory support.[27](**) 
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CONCLUSIONS 
Technological improvement has permitted the creation of new 
devices that are able to perform extracorporeal CO2 removal at lower 
blood flows with less invasiveness. However our knowledge is limited to 
case reports and case series studies.  Future randomized clinical trials that 
will soon be initiated various studies will help physicians to consider 
minimally invasive extracorporeal CO2 removal devices, coupled with 
mechanical ventilation setting as an alternative to mechanical ventilation 
alone to prevent and/or minimize side effects of ventilatory support.  
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Table 1: 
Extracorporeal support techniques  
 
Table 2: 
Characteristics of the LFPPV–ECCO2-R devices used in some of the 
largest studies from 1984 to 2009. 
 
